Neil Katherine, Marcil Allison, Kosar Lynette, Dumont Zack, Ruda Lisa, McMillan Kaitlyn
, BSP, ACPR (formerly Katherine Lang) was, at the time this study was performed, with the Department of Pharmacy Services, Regina Qu'Appelle Health Region, Regina, Saskatchewan. She is now with the Pharmacy Department, Prairie North Health Region, Lloydminster, Saskatchewan.
Can J Hosp Pharm. 2013 Sep;66(5):280-8. doi: 10.4212/cjhp.v66i5.1284.
Opioid analgesics are high-alert medications known to cause adverse drug events.
The purpose of this study was to determine the cause of opioid incidents requiring administration of naloxone, an opioid reversal agent. The specific objectives were to determine the number of opioid incidents and the proportion of incidents documented through occurrence reporting and to characterize the incidents by phase in the medication-use process, by type of incident, and by drug responsible for toxic effects.
A retrospective chart analysis was conducted using records from 2 acute care centres in the Regina Qu'Appelle Health Region. The study included inpatients who received naloxone for reversal of opioid toxicity resulting from licit, in-hospital opioid use. Cases were classified as preventable or nonpreventable. Preventable cases were analyzed to determine the phase of the medication-use process during which the incident occurred. These cases were also grouped thematically by the type of incident. The drug most likely responsible for opioid toxicity was determined for each case. The proportion of cases documented by occurrence reporting was also noted.
Thirty-six cases involving administration of naloxone were identified, of which 29 (81%) were deemed preventable. Of these 29 preventable cases, the primary medication incident occurred most frequently in the prescribing phase (23 [79%]), but multiple phases were often involved. The cases were grouped into 6 themes according to the type of incident. Morphine was the drug that most frequently resulted in toxic effects (18 cases [50%]). Only two of the cases (5.6%) were documented by occurrence reports.
Preventable opioid incidents occurred in the acute care centres under study. A combination of medication safety initiatives involving multiple disciplines may be required to decrease the incidence of these events and to better document their occurrence.
阿片类镇痛药是已知会导致药物不良事件的高警示药物。
本研究的目的是确定需要使用阿片类逆转剂纳洛酮的阿片类事件的原因。具体目标是确定阿片类事件的数量以及通过事件报告记录的事件比例,并按用药过程阶段、事件类型以及导致毒性作用的药物对事件进行特征描述。
使用里贾纳夸阿佩尔健康区域内两家急性护理中心的记录进行回顾性图表分析。该研究纳入了因合法的院内阿片类药物使用导致阿片类毒性反应而接受纳洛酮治疗的住院患者。病例被分类为可预防或不可预防。对可预防病例进行分析以确定事件发生时的用药过程阶段。这些病例还按事件类型进行主题分组。确定每个病例中最可能导致阿片类毒性的药物。还记录了通过事件报告记录的病例比例。
确定了36例涉及使用纳洛酮的病例,其中29例(81%)被认为是可预防的。在这29例可预防病例中,主要用药事件最常发生在处方阶段(23例[79%]),但通常涉及多个阶段。根据事件类型,病例被分为6个主题。吗啡是最常导致毒性作用的药物(18例[50%])。只有两例(5.6%)通过事件报告记录。
在所研究的急性护理中心发生了可预防的阿片类事件。可能需要涉及多个学科的药物安全举措组合来降低这些事件的发生率并更好地记录其发生情况。